香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不發表 任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚賴該等內容而引致的任何損失承擔任 何責任。 6030 孫毅先生之履歷詳情載列如下： 孫毅先生，53歲，現任本公司高級管理層成員、投資銀行黨委書記、投資銀行管理委員 會（「投行委」）主任。孫先生於1998年加入本公司，曾任本公司投資銀行部副總經理，中 信證券國際有限公司董事總經理，本公司投行委運營部負責人、資本市場部負責人、交 通行業組負責人，華夏基金管理有限公司副總經理兼華夏資本管理有限公司總經理，本 公司投行委委員兼金融與科技行業組負責人、並購業務線負責人，投行委副主任、聯席 主任。孫先生現亦任中信證券（香港）有限公司、中信里昂證券有限公司董事，中國證券 業協會第八屆投資銀行專業委員會副主任委員，中國資本市場學會第一屆創新發展專業 委員會委員，北京證券交易所第二屆證券發行承銷自律委員會委員。孫先生於1993年獲 江西財經大學經濟學學士學位，1996年獲廈門大學經濟學碩士學位。 截至目前，孫毅先生未持有本公司股份，不存在《上海證券交易所上市公司自 ...

Core Viewpoint - Youcare Pharmaceutical Group Co., Ltd. (悦康药业) has submitted its prospectus for an IPO on the Hong Kong Stock Exchange, aiming to expand its market presence after being listed on the A-share market since December 2020, with a current market capitalization of approximately RMB 10.4 billion [1][16]. Business Overview - Established in 2001, Youcare Pharmaceutical is a biopharmaceutical company with a diverse portfolio of commercially recognized products, focusing on research, development, production, and commercialization of therapies including oligonucleotides, mRNA vaccines, peptides, and innovative traditional Chinese medicine [2][17]. - Key products include Youcare Tong® (Ginkgo biloba extract injection) for managing cerebrovascular and peripheral vascular disorders, Ailisi® (Sildenafil citrate tablets) for treating erectile dysfunction, and other significant products like Liweike® (Omeprazole enteric-coated capsules) and Yuedaning® (Metformin sustained-release tablets) [2][17]. Pipeline and R&D - The company's pipeline includes innovative candidates across various stages, focusing on four core modalities: oligonucleotides, mRNA vaccines, peptides, and innovative traditional Chinese medicine [4][19]. - Notable projects include YKYY013 for chronic hepatitis B, YKYY015 targeting PCSK9 for cardiovascular metabolism, and YKYY029 for hypertension, all of which have received clinical trial approvals in China and the U.S. [4][19]. - In the mRNA vaccine segment, projects YKYY025 and YKYY026 aim to prevent RSV and varicella-zoster virus infections, respectively, with U.S. clinical trial approvals [4][19]. Financial Performance - For the fiscal years ending December 31, 2022, 2023, and 2024, and the first seven months of 2025, Youcare Pharmaceutical reported revenues of RMB 4.52 billion, RMB 4.18 billion, RMB 3.77 billion, and RMB 1.30 billion, respectively, with corresponding net profits of RMB 339 million, RMB 187 million, RMB 121 million, and a loss of RMB 146 million [12][27]. - The revenue breakdown shows significant contributions from cardiovascular, anti-infection, digestive system, and diabetes-related products, with cardiovascular products generating RMB 2.76 billion in 2022 [6][21]. Shareholding Structure - Prior to the Hong Kong listing, the major shareholders include Mr. Yu Weishi and Ms. Ma Guiying, who collectively hold approximately 48.65% of the company, making them the controlling shareholders [7][22]. Board of Directors - The board consists of 11 members, including 7 executive directors led by Mr. Yu Weishi as Chairman and Mr. Yu Fei as General Manager, along with 4 non-executive directors with diverse backgrounds in finance and healthcare [10][25].

Group 1 - The core point of the news is that Haitong Development (603162.SH) is currently experiencing a decline in stock price, closing at 12.29 yuan with a drop of 3.61% [1] - Haitong Development was listed on the Shanghai Stock Exchange on March 29, 2023, with an initial issuance of 41,276,015 shares at a price of 37.25 yuan per share, and the stock is currently in a state of decline [1] - The total amount raised from the initial public offering (IPO) was 153,753.16 million yuan, with a net amount of 142,793.20 million yuan intended for various projects including the purchase of flexible bulk carriers and system upgrades [1] Group 2 - On November 12, 2023, Haitong Development announced that it received approval from the Shanghai Stock Exchange for a specific stock issuance, aiming to raise up to 21,000.00 million yuan for bulk carrier purchases [2] - The company announced a cash dividend of 0.20 yuan per share and a capital reserve increase of 0.48 shares per share, resulting in a total distribution of 82,552,030 yuan in cash dividends and an increase of 198,124,872 shares [2] - Haitong Development plans to distribute a cash dividend of 0.15 yuan per share for the 2023 fiscal year, with a total cash dividend of 92,218,203.30 yuan based on a total share count of 614,788,022 shares, and intends to increase capital by 4.80 shares for every 10 shares held [3]

Core Viewpoint - The globalization of China's industrial chain and the increasing demand for cross-border asset allocation by domestic institutions and residents, along with the deepening of China's capital market opening policies, provide favorable opportunities and strong momentum for the development of international business by domestic securities firms [1] Group 1: Historical Development Opportunities for Securities Firms - The internationalization of China's industrial chain has significantly increased the demand for cross-border financial services, with non-financial direct investment by domestic investors abroad expected to reach USD 143.9 billion in 2024, a year-on-year growth of 10.54% [2] - Over 50% of A-share companies have disclosed overseas business income, indicating that going global is now a common phenomenon, with 33.36% of listed companies having over 30% of their income from overseas [2] Group 2: Growth in Cross-Border Investment Demand - The cross-border investment demand from institutions and residents has been strong, with foreign securities investment assets increasing from USD 1019.6 billion to USD 1694.1 billion from mid-2022 to mid-2025, reflecting an annual compound growth rate of 18.44% [6] - Foreign institutions' investment in domestic securities has also grown, with the market value of foreign holdings in domestic stocks and securities rising from USD 737.5 billion to USD 1071.8 billion from mid-2020 to mid-2025, with a compound annual growth rate of 7.76% [6] Group 3: Capital Market Opening and Securities Firms' Internationalization - China's accelerated financial market opening has created a favorable policy environment for the internationalization of securities firms, with various mutual recognition and cross-border financial policies being implemented [7] - The trading volume of the Hong Kong Stock Connect has increased from CNY 620.4 billion in 2015 to CNY 16.27 trillion by the end of 2025, reflecting a compound annual growth rate of 38.64% [7] Group 4: Market Landscape and Development Prospects of Securities Firms' International Business - Securities firms' international business encompasses various lines, including cross-border brokerage, wealth management, asset management, proprietary trading, and emerging digital asset businesses, with significant growth potential [9] Group 5: Cross-Border Brokerage and Trading Business - Chinese securities firms provide cross-border trading channels for clients, utilizing overseas subsidiaries to offer access to foreign stocks, bonds, and derivatives [10] Group 6: Cross-Border Wealth Management Business - The cross-border wealth management business is becoming a key development direction for securities firms, driven by the increasing demand for diversified asset allocation among Chinese residents [15] - The cross-border wealth management products of leading firms like CITIC Securities have seen rapid growth, with overseas product sales reaching USD 8.7 billion in 2024, a year-on-year increase of 151% [17] Group 7: Cross-Border Asset Management Business - The global asset management industry is increasingly focusing on cross-border asset management to capture growth cycles and interest rate differentials across different economies [19] Group 8: Overseas Investment Banking Business - Hong Kong serves as a critical hub for domestic securities firms' overseas investment banking activities, with supportive policies for mainland companies listing in Hong Kong [24] - The scale of equity financing in Hong Kong has significantly increased, with the total equity financing amount reaching HKD 590.6 billion in 2025, 3.26 times that of 2024 [25] Group 9: Overseas Proprietary Business - The overseas proprietary business has become a core profit source for leading securities firms, with a significant portion of their fixed-income investments being allocated to overseas markets [29] Group 10: Second Growth Curve for Securities Firms' International Business - The international business of securities firms is becoming an important revenue component, with firms like Huatai Securities and CITIC Securities showing strong growth in overseas business income [32] - The return on equity (ROE) for international subsidiaries of firms like CITIC Securities is significantly higher than their overall ROE, indicating better profit generation capabilities [34]

中信证券股份有限公司 董事会秘书工作细则 | 制定主体 | 董事会办公室 | | --- | --- | | 生效时间 | 2025年12月 | | | □公司治理制度 | | | ☑基本管理制度 | | 制度类别 | □公司经营管理制度 | | | □部门管理制度 | | 历史版本信息 | 2011年5 月经公司第四届董事会第二十七次会议审议制定 | | | 2025年12月经公司第八届董事会第四十二次会议审议修订 | 第一章 总则 第一条 为规范中信证券股份有限公司（以下简称公 司）董事会秘书履行工作职责，提高公司治理水平，规范公 司董事会秘书的选任、履职工作，根据《中华人民共和国公 司法》（以下简称《公司法》）、《中华人民共和国证券法》、 《上海证券交易所股票上市规则》（以下简称《上交所上市 规则》）等法律、行政法规、规章、规范性文件以及《中信 证券股份有限公司章程》（以下简称公司《章程》）的规定， 结合公司实际情况，制定本工作细则。 第二条 公司设董事会秘书一名，董事会秘书为公司高 级管理人员，对公司和董事会负责，董事会秘书应忠实、勤 勉地履行职责。 第三条 董事会秘书为公司与上海证券交易所的指定 联 ...

中信证券股份有限公司 独立董事工作制度 | 制定主体 | 董事会办公室 | | --- | --- | | 生效时间 | 2025年 12月 | | 制度类别 | □公司治理制度 □公司经营管理制度 | | | ☑基本管理制度 | | | □部门管理制度 | | 历史版本信息 | 2008年 7 月经公司第三届董事会第二十八次会议审议制定 | | | 2022年 12月经公司第七届董事会第四十八次会议审议修订 | | | 2023年 12月经公司第八届董事会第十四次会议审议修订 | | | 2025年 12月经公司第八届董事会第四十二次会议审议修订 | 第二条 独立董事是指不在公司担任除董事外的其他 职务，并与公司及公司主要股东不存在直接或者间接利害 关系，或者其他可能妨碍其进行独立客观判断关系的董事。 第三条 独立董事对公司及全体股东负有忠实与勤勉 义务。独立董事应当按照法律、行政法规、中国证监会规 定、证券交易所业务规则、公司《章程》和本制度的要求， 认真履行职责，在董事会中发挥参与决策、监督制衡、专 业咨询作用，维护公司整体利益，保护中小股东合法权益。 若个别实体的利益有悖于整体股东的利益，则独立董事的 ...

中信证券股份有限公司 董事会发展战略与ESG委员会议事规则 | 制定主体 | 董事会办公室 | | --- | --- | | 生效时间 | 2025年12月 | | | 公司治理制度 | | | □基本管理制度 | | 制度类别 | □公司经营管理制度 | | | □部门管理制度 | | | 2002年4月经公司第一届董事会第四次会议审议制定 | | | 2011年9月经公司第四届董事会第三十三次会议审议修订 | | 历史版本信息 | 2022年1月经公司第七届董事会第三十四次会议审议修订 | | | 2023年12月经公司第八届董事会第十四次会议审议修订 | | | 2025年12月经公司第八届董事会第四十二次会议审议修订 | 第一章 总则 第一条 为健全和规范中信证券股份有限公司（下称公司） 董事会发展战略与ESG委员会（下称发展战略与ESG委员会）的议 事和决策程序，提高发展战略与ESG委员会的工作效率和科学决 策水平，保证发展战略与ESG委员会工作的顺利进行，根据国家 有关法律、法规、规范性文件、公司股票上市地（下称上市地） 上市规则和《中信证券股份有限公司章程》（下称公司《章程》） 的有关规定， ...

中信证券股份有限公司 董事和高级管理人员 持有本公司股份及其变动管理办法 | 制定主体 | 董事会办公室 | | | --- | --- | --- | | 生效时间 | 2025年 12月 | | | | □公司治理制度 ☑基本管理制度 | | | 制度类别 | □公司经营管理制度 | | | | □部门管理制度 | | | | 2008年 3 | 月经公司第三届董事会第二十三次会议审议制定 | | 历史版本信息 | 2023年 5 | 月经公司第八届董事会第七次会议审议修订 | | | 2025年 | 12月经公司第八届董事会第四十二次会议审议修订 | 第一章 总则 第一条 根据《中华人民共和国公司法》《中华人民 共和国证券法》《上市公司股东减持股份管理暂行办法》 《上市公司董事和高级管理人员所持本公司股份及其变动 管理规则》《上海证券交易所上市公司自律监管指引第 15 号——股东及董事、高级管理人员减持股份》、香港法例 第五百七十一章《证券及期货条例》《香港联合交易所有限 公司证券上市规则》等法律、行政法规、中国证券监督管 理委员会（以下简称中国证监会）规定、证券交易所规则 以及《中信证券股份有限公司章 ...

中信证券股份有限公司 董事会风险管理委员会议事规则 | 制定主体 | 董事会办公室 | | --- | --- | | 生效时间 | 2025年12月 | | 制度类别 | 公司治理制度 | | | □基本管理制度 | | | □公司经营管理制度 | | | □部门管理制度 | | 历史版本信息 | 2004年3月经公司第二届董事会第七次会议审议制定 | | | 2011年9月经公司第四届董事会第三十三次会议审议修订 | | | 2016年4月经公司第六届董事会第三次会议审议修订 | | | 2018年3月经公司第六届董事会第二十二次会议审议修订 | | | 2023年12月经公司第八届董事会第十四次会议审议修订 | | | 2025年12月经公司第八届董事会第四十二次会议审议修订 | 第一章 总则 第一条 为健全和规范中信证券股份有限公司（下称公司） 董事会风险管理委员会（下称风险管理委员会）的议事和决策程 序，提高风险管理委员会的工作效率和科学决策水平，保证风险 管理委员会工作的顺利进行，根据国家有关法律、法规、规范性文 件、公司股票上市地（下称上市地）上市规则和《中信证券股份有 限公司章程》（下称公司 ...

中信证券股份有限公司 董事会薪酬与考核委员会议事规则 | 制定主体 | 董事会办公室 | | --- | --- | | 生效时间 | 2025年12月 | | 制度类别 | 公司治理制度 | | | □基本管理制度 | | | □公司经营管理制度 | | | □部门管理制度 | | 历史版本信息 | 2004年12月经公司第二届董事会第十五次会议审议制定 | | | 2011年9月经公司第四届董事会第三十三次会议审议修订 | | | 2011年12月经公司第四届董事会第三十六次会议审议修订 | | | 2023年5月经公司第八届董事会第七次会议审议修订 | | | 2023年12月经公司第八届董事会第十四次会议审议修订 | | | 2025年12月经公司第八届董事会第四十二次会议审议修订 | 第一章 总则 第一条 为进一步建立健全中信证券股份有限公司（下称公 司）董事及高级管理人员的考核和薪酬管理制度，完善公司治理 结构，根据国家有关法律、法规和规范性文件、公司股票上市地 （下称上市地）上市规则和《中信证券股份有限公司章程》（下 称公司《章程》）的有关规定，公司特设立董事会薪酬与考核委 员会，并制定本议事 ...